減肥手術市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190025

減肥手術市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Bariatric Surgery Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內,減肥手術市場預計將以 5.7% 的複合年增長率增長。

對於市場而言,預計 COVID-19 大流行將產生重大影響。 診斷和外科行業受到全球封鎖措施的影響,這些措施減少了公眾流動性。 根據美國代謝與減肥外科醫師協會 (ASMBS) 的說法,減肥手術被認為是一種非緊急手術,導致這些手術被擱置,成功率也在下降。 根據最近的一項研究,即 COVID-19 大流行期間醫生和患者的減肥手術,2020 年 9 月,COVID-19 大流行期間的病態肥胖以及手術風險和並發症的增加導致減肥計劃減少。虛擬會診和遠程醫療被認為適合繼續進行。 肥胖人群容易受到心理和生理條件的影響,這阻礙了大流行性肥胖症的管理。 柳葉刀論文《2020 年 COVID-19 大流行期間和之後的減肥和代謝手術》指出,大流行將對肥胖治療產生重大影響,使數百萬兒童、青少年和成人面臨合併症加重的風險。接受治療,並且更有可能出現較差的 COVID-19 結果。 因此,大量的 COVID-19 陽性患者和對全球醫療保健系統的巨大影響是導致幾種肥胖治療藥物下降的原因,從而對 2020 年和 2021 年的市場產生了負面影響。略有影響。

推動肥胖減肥手術市場增長的主要因素是人口中肥胖患病率上升以及 2 型糖尿病和心髒病患病率上升。 體內脂肪多的人更容易患糖尿病。 因此,患者在減肥手術中採取一定的措施來預防肥胖。 例如,根據世界衛生組織(WHO)2022年5月關於歐洲區域的報告,在世界衛生組織歐洲區域,超過60%的成年人、29%的年輕男孩和27%的年輕女孩超重或肥胖。並且根據根據該報告,超重和肥胖在該地區的非傳染性疾病危險因素中排名第四,僅次於高血壓、不健康飲食和吸煙。 此外,根據國際糖尿病聯合會 2021 年 12 月的報告,2021 年全球約有 5.37 億 20-79 歲的成年人患有糖尿病,到 2030 年這一數字將增加,預計將增至 6.43 億。 因此,由於肥胖的高負擔和肥胖風險因素的流行,預計將在預測期內推動減肥手術市場的增長。

此外,肥胖患病率的上升將增加對減肥手術的需求,這將有助於擴大市場。 根據世界衛生組織 2021 年 6 月的數據,2020 年有 3900 萬五歲以下兒童超重或肥胖。 據估計,2019 年有 3820 萬 5 歲以下兒童超重或肥胖。 超重和肥胖曾經被認為只是高收入國家的問題,但現在在低收入和中等收入國家尤其是城市地區很普遍。 自 2000 年以來,非洲五歲以下超重兒童的比例增加了近 24%。 根據世界肥胖聯盟發布的 2022 年 3 月世界肥胖地圖集,到 2030 年,全球將有 10 億人肥胖,其中包括五分之一的女性和七分之一的男性。我預測。 因此,由於肥胖患病率上升和手術需求增加,預計減肥手術市場將在預測期內增長。

此外,市場的擴張得到了主要市場參與者採取的各種戰略的支持,例如資助研發以擴大減肥手術的範圍。 例如,2021 年 6 月,總部位於辛辛那提的 Standard Bariatrics, Inc. 開發了 Titan SGS,這是同類產品中的首創設計,可讓外科醫生進行袖狀胃切除術,這是治療肥胖病的頂級減肥手術。6,2021 年5 月,總部位於辛辛那提的 Standard Variatrix 開發了 Titan SGS,以幫助外科醫生進行袖狀胃切除術,這是針對肥胖症的頂級減肥手術。 此外,2021 年 6 月,Standard Bariatrics 獲得了 3500 萬美元的 B 系列資金,以加速其第一個用於袖狀胃成形術的減肥手術平台的開發和商業化。

因此,很明顯,糖尿病和肥胖患病率的上升將在未來幾年顯著推動減肥手術市場。 然而,高昂的手術費用可能會抑制市場增長。

減肥手術市場趨勢

胃球囊有望在植入器械領域保持高複合年增長率

胃氣球,也稱為胃內氣球 (IGB) 或胃氣球,是一種可膨脹的醫療工具,可瞬間插入胃中以幫助減輕體重。 新產品的推出、患者意識的提高、與減肥手術中心的合作以及製造優化以提高運營槓桿是推動球囊需求的一些因素。

美國批准的胃氣球包括 ReShape Duo Balloon 和 ORBERA Balloon。 2019年5月,Spatz Medical宣布其新推出的Spatz3球囊在一系列臨床試驗中獲得美國FDA批准,其療效明顯優於市場上任何不可調節球囊。 然而,市場參與者正在採用多種不同的策略,例如籌款和產品發布流程。 胃排空氣球製造商 Allurion Technologies 已籌集了 3400 萬美元的額外資金,以加速 Elipse Balloon 的商業化努力和進入美國市場。 因此,由於上述原因,胃氣球部分有望在預測期內推動。

北美主導市場,預計在預測期內也會如此

北美預計將在整個預測期內主導整個市場。 這是由於整個地區的肥胖人數不斷增加。 它還受到該地區更好的醫療保健基礎設施的可用性以及減肥手術意識的提高的推動。 在北美地區,美國占據了最大的市場份額。 根據美國疾病控制與預防中心 (CDC) 2022 年 5 月的數據,從 2017 年 3 月到 2020 年 3 月,41.9% 的美國人肥胖。 美國的肥胖患病率從 30.5% 上升到 41.9%。 同期,嚴重肥胖的患病率從 4.7% 上升到 9.2%。 CDC 已將肥胖確定為美國第一大可預防死因,也是全球和美國慢性病的主要原因之一。 與肥胖相關的疾病,稱為合併症,包括心血管疾病、糖尿病、肌肉骨骼疾病和某些癌症。

根據2021年6月發布的美國國家健康統計報告,在20歲以上的成年人中,肥胖患病率為41.9%,重度肥胖患病率為9.2%,糖尿病患病率為14.8%。 預計人口中肥胖患病率的增加將推動美國的減肥手術市場。 此外,該國擁有完善的醫療保健基礎設施以及眾多市場參與者的存在,預計將在預測期內推動市場增長。 例如,2020 年 9 月,強生醫療器械公司旗下的 Ethicon 推出了 ECHELON ENDOPATH Staple Line Reinforcement (SLR),這是一種旨在減少減肥手術期間可能發生的並發症的支撐裝置。現已上市銷售。

此外,預計該地區主要市場參與者推出的產品將推動市場增長。發布了該設備。 POWERSEAL 設備可用於多種形式的外科手術,包括減肥手術。 同樣,2021 年 6 月,強生醫療器械公司旗下的 Ethicon 推出了 ENSEAL X1 Curved Jaw Tissue Sealer,用於結直腸、婦科、減肥手術和胸部手術。

這樣一來,美國肥胖症的高患病率、越來越多地採用減肥手術以及不斷上升的保險覆蓋率將導致預測期內減肥手術市場的增長有望領先。

減肥手術市場競爭分析

減肥手術市場競爭適中,由幾家主要參與者組成。 就市場份額而言,幾家主要參與者目前主導著市場。 隨著患者意識水平的提高和肥胖人口的增加,預計未來幾年其他幾家中小企業也將進入市場。 主要參與者包括 Medtronic PLC、Ethicon Inc.、Apollo Endosurgery Inc. 和 Intuitive Surgical Inc.。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 肥胖患者增加
    • 2 型糖尿病和心髒病的患病率
    • 政府控制肥胖的努力
  • 市場製約因素
    • 手術費用高
    • 發展中國家和欠發達國家缺乏知識和意識
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:百萬美元)

  • 按設備
    • 輔助設備
      • 縫合裝置
      • 關閉裝置
      • 裝訂裝置
      • 拖釣者
      • 其他輔助設備
    • 植入式設備
      • 胃帶
      • 電刺激器
      • 胃氣球
      • 胃瘺
    • 其他設備
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 西班牙
      • 意大利
      • 法國
      • 其他歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Medtronic PLC
    • Ethicon Inc.(Johnson and Johnson)
    • Apollo Endosurgery Inc.
    • Aspire Bariatrics Inc.
    • Intuitive Surgical Inc.
    • B. Braun Melsungen AG
    • Olympus Corporation
    • The Cooper Companies
    • Conmed Corporation
    • Cousin Biotech
    • Cook Medical

第7章 市場機會與今後動向

簡介目錄
Product Code: 52146

The Bariatric Surgery Market is poised to grow at a CAGR of 5.7% during the forecast period, 2022-2027.

On the market, the COVID-19 pandemic is anticipated to have a significant effect. The diagnostic and surgical industries have been impacted by the global lockdown measures, which have also decreased public mobility. As per the American Society for Metabolic & Bariatric Surgery (ASMBS), bariatric surgeries are considered non-emergent procedures, as a result, these procedures were on hold and their success rate has declined. As per a recent study 'Bariatric Surgery During the COVID-19 Pandemic the Perspective of Physicians and Patients', in September 2020, virtual consultation and telemedicine were considered suitable to continue weight loss programs, as the risks and complications of morbid obesity and surgery during the COVID-19 pandemic were high. The obese population is vulnerable to psychological and physiological conditions, which have hurt the pandemic's management of obesity. According to the Lancet article 'Bariatric and metabolic surgery during and after the COVID-19 pandemic' 2020, the pandemic has had a significant impact on obesity treatment, putting millions of children, adolescents, and adults at risk for worsening comorbidities, limiting their access to care and raising their chances of having poor COVID-19 outcomes. Thus, a large number of COVID-19 positive patients and its significant effect on healthcare systems across the world are responsible for the decline in several bariatric procedures and thereby negatively impacted the market in 2020 and slightly in 2021.

The major factors attributing to the growth of the bariatric surgery market are an increase in obesity among people and a rising prevalence rate of Type 2 diabetes and heart diseases. People with more fat in their bodies are highly likely to be affected by diabetes. Hence, patients are taking certain measures to prevent obesity with bariatric surgeries. For instance, according to the World Health Organization (WHO) May 2022 report on the European region, in the WHO European Region, over 60% of adults and 29% of boys and 27% of girls who are children are overweight or obese and also, as per the same report, overweight and obesity rank fourth among the risk factors for non-communicable diseases in the region, after high blood pressure, unhealthy eating, and cigarette use. Further, according to the December 2021 report of the International Diabetes Federation, it is estimated that about 537 million adults in the age group of 20-79 years were living with diabetes in 2021 across the world and this number is projected to increase to 643 million by 2030. Hence, owing to the high burden of obesity and the increasing prevalence of risk factors for obesity are expected to fuel growth in the bariatric surgery market over the forecast period.

Additionally, the rising prevalence of obesity increases the demand for bariatric surgery, which helps the market expand. According to the World Health Organization in June 2021, there were 39 million under-five years old kids who were overweight or obese 2020. In addition, it was estimated that 38.2 million kids under the age of 5 were overweight or obese in 2019. Overweight and obesity, once thought to be a problem only in high-income nations are now becoming more prevalent in low- and middle-income nations as well, especially in urban areas. Since 2000, there has been a nearly 24% increase in the proportion of under-five overweight children in Africa. Moreover, World Obesity Atlas March 2022 published by the World Obesity Federation, predicts that by 2030, one billion people worldwide, including one in five women and one in seven men, will have obesity. As a result, the market for bariatric surgery is anticipated to grow over the projection period due to the rising prevalence of obesity and the increased need for the procedure.

Furthermore, the market expansion is supported by a variety of strategies employed by the major market players, such as funding for research and development to broaden the scope of bariatric surgery. For Instance, In June 2021, Cincinnati-based Standard Bariatrics, Inc., developed the Titan SGS, a first-of-its-kind design that offers surgeons to perform sleeve gastrectomy, the top bariatric surgical procedure for obesity disease. Additionally in June 2021, to expedite the development and commercialization of their first bariatric surgical platform for sleeve gastroplasty, Standard Bariatrics has secured USD 35 million in Series B funding.

Therefore, it is clear that the growing prevalence of diabetes and obesity will significantly drive the market for bariatric surgery over the upcoming years. However, the high cost of surgery may restrain the market growth.

Bariatric Surgery Market Trends

Gastric Balloons is Expected to Record a High CAGR in the Implantable Device Segment

A gastric balloon also referred to as an intragastric balloon (IGB) or a stomach balloon, is an inflatable medical tool that is momentarily inserted into the stomach to aid in weight loss. The introduction of new products, an increase in patient awareness, collaboration with bariatric surgery centers, and manufacturing optimization to increase operating leverage are some of the factors that are driving the demand for balloons.

According to the study titled "Endoscopic intragastric balloon: a gimmick or a viable option for obesity?" published in the Annals of Transitional Medicine in March 2020, the Orbera gastric balloon results in a pooled total body weight loss (TBWL) of 13.16% after 6 months. Additionally, there was a 26.9 percent excess weight loss compared to controls. Thus, the efficacy of the gastric balloon to treat obesity and help in reducing weight supports the market growth.

Some of the approved Gastric Balloons in United States include the ReShape Duo Balloon and the ORBERA Balloon. In May 2019, Spatz Medical announced that its newly launched Spatz3 balloon is significantly more effective than any non-adjustable balloon in the market as approved by United States FDA in a series of clinical trials. However, market players have employed several different strategies such as the funding and product launch processes. Manufacturer of gastric weight-loss balloons Allurion Technologies has increased its funding by USD 34 million to accelerate its commercialization efforts and entry into the U.S. market for its Elipse Balloon. Thus, due to the above-mentioned reasons, the gastric balloon segment is expected to propel over the forecast period.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. This is due to the increasing number of obese populations across the region. Another driving factor is the availability of better healthcare infrastructure in the region and the rising awareness of bariatric surgery. In the North American region, United States holds the largest market share. According to the Centers for Disease Control and Prevention (CDC) in May 2022, from March 2017 to March 2020, 41.9 percent of Americans were obese. The prevalence of obesity in United States increased from 30.5 to 41.9 percent. The prevalence of severe obesity rose from 4.7% to 9.2% during the same period. The CDC has identified obesity as a leading cause of preventable death in United States, and it is one of the leading causes of chronic diseases both worldwide and in United States. Obesity-related disorders, known as comorbidities, include cardiovascular diseases, diabetes, musculoskeletal disorders, and some cancers.

As per United States, National Health Statistics Reports published in June 2021, among adults aged 20 and over, the prevalence of obesity was 41.9%, severe obesity was 9.2%, and diabetes was 14.8%. The increase in the prevalence of obesity among the population is expected to drive the bariatric surgery market in United States. Furthermore, the presence of an established healthcare infrastructure along with the presence of a large number of market players in the country is expected to boost market growth over the forecast period. For instance, in September 2020, Ethicon, part of Johnson & Johnson Medical Devices Companies, launched ECHELON ENDOPATH Staple Line Reinforcement (SLR), a buttressing device designed to reduce potential complications during bariatric procedures

Furthermore, product launches by the key market players in the region are expected to boost the market growth For Instance, in September 2021, Olympus launched the POWERSEAL advanced bipolar surgical energy devices to Strengthen its Surgical Portfolio. The POWERSEAL devices can be used in numerous forms of surgical intervention including bariatric surgical procedures. Similarly, in June 2021, Ethicon, part of the Johnson & Johnson Medical Devices Companies launched the ENSEAL X1 Curved Jaw Tissue Sealer for colorectal, gynecological, bariatric surgery, and thoracic procedures.

Thus, the high prevalence of obesity and the increasing adoption of bariatric surgeries in United States, along with increasing insurance coverage, are expected to drive the bariatric surgery market during the forecast period.

Bariatric Surgery Market Competitive Analysis

The bariatric surgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and increasing obese population, few other smaller players are also expected to enter into the market in the coming years. Some of the major players of the market are Medtronic PLC, Ethicon Inc., Apollo Endosurgery Inc., and Intuitive Surgical Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Obesity Patients
    • 4.2.2 Prevalence Rate of Type 2 Diabetes and Heart Diseases
    • 4.2.3 Government Initiatives to Curb Obesity
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Surgery
    • 4.3.2 Lack of Knowledge and Awareness in Developing and Underdeveloped Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Device
    • 5.1.1 Assisting Devices
      • 5.1.1.1 Suturing Device
      • 5.1.1.2 Closure Device
      • 5.1.1.3 Stapling Device
      • 5.1.1.4 Trocars
      • 5.1.1.5 Other Assisting Devices
    • 5.1.2 Implantable Devices
      • 5.1.2.1 Gastric Bands
      • 5.1.2.2 Electrical Stimulation Devices
      • 5.1.2.3 Gastric Balloons
      • 5.1.2.4 Gastric Emptying
    • 5.1.3 Other Devices
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 Spain
      • 5.2.2.4 Italy
      • 5.2.2.5 France
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic PLC
    • 6.1.2 Ethicon Inc. (Johnson and Johnson)
    • 6.1.3 Apollo Endosurgery Inc.
    • 6.1.4 Aspire Bariatrics Inc.
    • 6.1.5 Intuitive Surgical Inc.
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 Olympus Corporation
    • 6.1.8 The Cooper Companies
    • 6.1.9 Conmed Corporation
    • 6.1.10 Cousin Biotech
    • 6.1.11 Cook Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS